|Mr. Jon P. Stonehouse||CEO, Pres & Director||889.84k||1.05M||1961|
|Mr. Thomas R. Staab II||CFO, Principal Accounting Officer, Sr. VP & Treasurer||656.11k||302.1k||1968|
|Dr. William P. Sheridan||Chief Medical Officer & Sr. VP||720.46k||507.35k||1955|
|Dr. Yarlagadda S. Babu||Sr. VP of Drug Discovery||614.35k||57.6k||1953|
|Mr. John D. Bluth||Sr. VP of Investor Relations & Corp. Communications||N/A||N/A||1973|
BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers oral and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor, for the treatment of acute uncomplicated influenza under the RAPIVAB, ALPIVAB, RAPIACTA, and PERAMIFLU names; and Mundesine, an oral purine nucleoside phosphorylase inhibitor for peripheral T-cell lymphoma. It is also developing BCX7353, an oral serine protease inhibitor and oral dose formulation that is in Phase III clinical trials to treat hereditary angioedema; BCX9930, an oral factor D inhibitor, which is in Phase I clinical trials for mediated diseases; BCX9250, an oral activin receptor-like kinase-2 inhibitors that is in preclinical trials to treat fibrodysplasia ossificans progressive; and Galidesivir, an RNA dependent-RNA polymerase inhibitor, which is in Phase I clinical trials to treat various RNA viruses, including Marburg, Yellow Fever, Ebola, and Zika. The company has collaborations and in-license relationships with U.S. Department of Health and Human Services; National Institute of Allergy and Infectious Diseases; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; Mundipharma International Holdings Limited; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.
BioCryst Pharmaceuticals, Inc.’s ISS Governance QualityScore as of October 4, 2019 is 5. The pillar scores are Audit: 2; Board: 4; Shareholder Rights: 8; Compensation: 5.